Extracellular vesicle-derived microbiome obtained from exhaled breath condensate in patients with asthma

An, Jin; McDowell, Andrea; Kim, Eui Chong; Kim, Tae‐Bum

doi:10.1016/j.anai.2021.02.030

Cited by 10 publications

(7 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Desferrioxamine E (FoxE), ferricrocin (Fc), TafC, Pch, and a ferriform of PvdE/PvdD were obtained from EMC Microcollections GmbH (Tübingen, Germany), and HHQ from Sigma-Aldrich (Prague, Czech Republic). Breath condensates were obtained as described [ 20 ]. Urine, serum, breath condensate, endotracheal aspirates, and lung tissue samples were subjected to two-step liquid–liquid extraction [ 21 ].…”

Section: Methodsmentioning

confidence: 99%

Noninvasive Combined Diagnosis and Monitoring of Aspergillus and Pseudomonas Infections: Proof of Concept

Dobiáš

Škríba

Pluháček

et al. 2021

JoF

View full text Add to dashboard Cite

In acutely ill patients, particularly in intensive care units or in mixed infections, time to a microbe-specific diagnosis is critical to a successful outcome of therapy. We report the application of evolving technologies involving mass spectrometry to diagnose and monitor a patient’s course. As proof of this concept, we studied five patients and used two rat models of mono-infection and coinfection. We report the noninvasive combined monitoring of Aspergillus fumigatus and Pseudomonas aeruginosa infection. The invasive coinfection was detected by monitoring the fungal triacetylfusarinine C and ferricrocin siderophore levels and the bacterial metabolites pyoverdin E, pyochelin, and 2-heptyl-4-quinolone, studied in the urine, endotracheal aspirate, or breath condensate. The coinfection was monitored by mass spectrometry followed by isotopic data filtering. In the rat infection model, detection indicated 100-fold more siderophores in urine compared to sera, indicating the diagnostic potential of urine sampling. The tools utilized in our studies can now be examined in large clinical series, where we could expect the accuracy and speed of diagnosis to be competitive with conventional methods and provide advantages in unraveling the complexities of mixed infections.

show abstract

Section: Methodsmentioning

confidence: 99%

Noninvasive Combined Diagnosis and Monitoring of Aspergillus and Pseudomonas Infections: Proof of Concept

Dobiáš

Škríba

Pluháček

et al. 2021

JoF

View full text Add to dashboard Cite

show abstract

“…It is interesting to note how this notion was obtained indirectly by analyzing the EVs released by these bacterial species. Thus, microvesicles can be used for diagnostic purposes (in integration with other specific examinations) [80]. Urine-released microbial extracellular vesicles can be potential and novel biomarkers for chronic respiratory diseases.…”

Section: Microbiome Extracellular Vesicles and Chronic Respiratory Di...mentioning

confidence: 99%

Extracellular Vesicles in Airway Homeostasis and Pathophysiology

et al. 2021

View full text Add to dashboard Cite

The epithelial–mesenchymal trophic unit (EMTU) is a morphofunctional entity involved in the maintenance of the homeostasis of airways as well as in the pathogenesis of several diseases, including asthma and chronic obstructive pulmonary disease (COPD). The “muco-microbiotic layer” (MML) is the innermost layer of airways made by microbiota elements (bacteria, viruses, archaea and fungi) and the surrounding mucous matrix. The MML homeostasis is also crucial for maintaining the healthy status of organs and its alteration is at the basis of airway disorders. Nanovesicles produced by EMTU and MML elements are probably the most important tool of communication among the different cell types, including inflammatory ones. How nanovesicles produced by EMTU and MML may affect the airway integrity, leading to the onset of asthma and COPD, as well as their putative use in therapy will be discussed here.

show abstract

“…Using the pre-existing data from COREA, distinct microbiota of patients with asthma compared with healthy controls by metagenomic analysis of extracellular vesicles in exhaled breath condensate (EBC) have been reported. [9] We have identified significant single nucleotide polymorphisms in Korean patients with asthma in genome-wide association studies. [10] The European U-BIOPRED consortium has also reported novel molecular phenotypes and markers in severe asthma based on proteomic, transcriptomic, and metabolomic data generated from blood, sputum, airway epithelial cells, and exhaled breath.…”

Section: Introductionmentioning

confidence: 99%

“…Previous work from the Cohort for Reality and Evolution of Adult Asthma in Korea (COREA) and Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) has initiated this omics approach. Using the pre-existing data from COREA, distinct microbiota of patients with asthma compared with healthy controls by metagenomic analysis of extracellular vesicles in exhaled breath condensate (EBC) have been reported [ 9 ]. We have identified significant single nucleotide polymorphisms in Korean patients with asthma in genome-wide association studies [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Precision Medicine Intervention in Severe Asthma (PRISM) study: molecular phenotyping of patients with severe asthma and response to biologics

et al. 2023

Self Cite

View full text Add to dashboard Cite

Severe asthma represents an important clinical unmet need despite the introduction of biologic agents. Although advanced omics technologies have aided researchers in identifying clinically relevant molecular pathways, there is lack of integrated omics approach in severe asthma particularly in terms of its evolution over time. The collaborative Korea-UK research project, Precision Medicine Intervention in Severe Asthma (PRISM), was launched in 2020 with the aim of identifying molecular phenotypes of severe asthma by analyzing multi-omics data encompassing genomics, epigenomics, transcriptomics, proteomics, metagenomics, and metabolomics. PRISM is a prospective, observational, and multicenter study involving patients with severe asthma attending severe asthma clinics in Korea and the UK. Data including patient demographics, inflammatory phenotype, medication, lung function, and control status of asthma will be collected along with biological samples (blood, sputum, urine, nasal epithelial cells, and exhaled breath condensate) for omics analyses. Follow-up evaluations will be performed at baseline, 1 month, 4–6 months, and 10–12 months to assess the stability of phenotype and treatment responses for those patients who have newly begun biologic therapy. Standalone and integrated omics data will be generated from the patient samples at each visit, paired with clinical information. By analyzing these data, we will identify the molecular pathways that drive lung function, asthma control status, acute exacerbations, and the requirement for daily oral corticosteroids and that are involved in the therapeutic response to biological therapy. PRISM will establish a large multi-omics dataset of severe asthma to identify potential key pathophysiological pathways of severe asthma.

show abstract

Extracellular vesicle-derived microbiome obtained from exhaled breath condensate in patients with asthma

Cited by 10 publications

References 8 publications

Noninvasive Combined Diagnosis and Monitoring of Aspergillus and Pseudomonas Infections: Proof of Concept

Noninvasive Combined Diagnosis and Monitoring of Aspergillus and Pseudomonas Infections: Proof of Concept

Extracellular Vesicles in Airway Homeostasis and Pathophysiology

Precision Medicine Intervention in Severe Asthma (PRISM) study: molecular phenotyping of patients with severe asthma and response to biologics

Contact Info

Product

Resources

About